Brevan Howard Capital Management LP
Institutional investor · Portfolio as of Q4 2020
Top Holdings26 positions
ISHARES TR | 600,000 | $117.8M | 23.6% | — | — | — | New — |
ISHARES TR | 1M | $51.7M | 10.4% | — | — | — | New — |
VANECK ETF TRUST | 1.4M | $51.1M | 10.3% | — | — | — | New — |
VANECK ETF TRUST | 200,000 | $43.7M | 8.8% | — | — | — | New — |
VANECK ETF TRUST | 1M | $36M | 7.2% | $34.11 | 0.00% | 1 qtr | New 92 |
GLOBAL X FDS | 550,000 | $25.1M | 5.0% | — | — | — | New — |
VANECK ETF TRUST | 660,000 | $23.8M | 4.8% | — | — | — | New — |
CME GROUP INC | 102,553 | $18.7M | 3.7% | $64.90 | +125.47% | 8 qtrssince 2016-Q1 | Unchanged 0 |
TWIST BIOSCIENCE CORP | 112,000 | $15.8M | 3.2% | $147.15 | 0.00% | 1 qtr | New 81 |
SELECT SECTOR SPDR TR | 350,000 | $13.3M | 2.7% | — | — | — | New — |
ISHARES INC | 426,082 | $11.3M | 2.3% | $22.46 | -13.25% | 1 qtr | New 75 |
FIRST TR EXCHANGE-TRADED FD | 143,850 | $10.1M | 2.0% | $68.74 | 0.00% | 1 qtr | New 75 |
INVESCO EXCHANGE TRADED FD T | 97,700 | $10.1M | 2.0% | $90.99 | 0.00% | 1 qtr | New 75 |
ARK ETF TR | 104,050 | $9.7M | 1.9% | $92.68 | -4.86% | 1 qtr | New 66 |
CLOUDFLARE INC | 111,500 | $8.5M | 1.7% | $77.53 | 0.00% | 1 qtr | New 66 |
FASTLY INC | 90,000 | $7.9M | 1.6% | $90.43 | 0.00% | 1 qtr | New 66 |
JD.COM INC | 74,500 | $6.5M | 1.3% | $77.02 | 0.00% | 1 qtr | New 65 |
EDITAS MEDICINE INC | 76,420 | $5.4M | 1.1% | $70.11 | 0.00% | 1 qtr | New 65 |
ISHARES TR | 185,000 | $5.2M | 1.0% | $26.29 | 0.00% | 1 qtr | New 65 |
BLOOM ENERGY CORP | 160,000 | $4.6M | 0.9% | $28.66 | 0.00% | 1 qtr | New 55 |
Brevan Howard Capital Management LP manages $498.6M across 26 positions as of Q4 2020. Top holdings: IWM calls (23.6%), EEM calls (10.4%), GDX calls (10.3%). Fund DNA: Diversified Scout. HoldingsIntel Score: 1.5/5.0.
Active quarter - 18 new positions, 29 exits, 0 increased. Top move: GDX (NEW, conviction 92). Portfolio: $499M across 26 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR